Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ESC cardiologists 'intrigued'by novel approach to heart failure

31.01.2012
Sophia Antipolis -- The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure¹.

In the "hypothesis generating" study, ursodeoxycholic acid (UDCA) delivered significant improvements in peak post ischemic blood flow in the arm, a trend for improvement in peak post ischemic blood flow in the leg, but failed to show benefits in exercise capacity and several inflammatory markers. Despite such conflicting data, ESC spokespersons believe that further exploration of UCDA is now justified in larger populations of heart failure patients.

"Although the study failed on two out of three counts , the observed improvements in post ischemic arm and leg blood flow make it highly unlikely such findings would have occurred purely by chance," says Professor Kenneth Dickstein, an ESC spokesperson. "The results are enough to pique real interest and suggest the approach has the potential to offer another string to our bow for improving heart failure symptoms."

It is also noteworthy, adds Dickstein from the University of Bergen (Stavanger University Hospital, Norway), that JACC felt the study to be of sufficient merit to commission an editorial².

The theory underlying the use of UDCA (a bile acid commonly used in the treatment of cholestatic liver disease) centres on the finding that abdominal congestion (caused by heart failure) leads to increased gut permeability, allowing endotoxins produced by gram negative bacteria to enter the circulation. The increased levels of proinflammatory cytokines can then further exacerbate symptoms of heart failure. UDCA is able to form a complex ("mixed micelles") around a component of the cell-wall of the gram-negative bacteria (lipopolysaccharide), thereby decreasing levels of proinflammatory cytokines and offering the potential to improve peripheral blood flow and ultimately increase exercise tolerance.

In the last 10 to 15 years studies have explored modifying inflammation in heart failure patients (through anti-inflammatory agents, antibiotics and statins), but all have proved neutral or in some cases even resulted in worse outcomes for patients.
In the current prospective double-blind, cross-over study, Stephan von Haehling, from the Charité Medical School (Berlin, Germany), and colleagues from Poland, UK, Austria and Italy, assessed the effects of UDCA on endothelial function and inflammatory markers in 17 chronic heart failure patients who received 500 mg UDCA twice daily for four weeks, followed by placebo for another four weeks. Results showed that in comparison with placebo, UDCA significantly improved peak post-ischemic blood flow in the arm (p=0.038), and showed a trend for improved peak blood flow in the leg (p=0.079). No change, however, occurred in the six-minute walk test and for New York Heart Association functional class, and furthermore, levels of tumour necrosis factor a and interleukin-6 remained unchanged.

"One difficulty is that the UDCA hypothesis follows a precise pathway, and the results fail to demonstrate each step of the pathway, i.e. show that improvements in peripheral blood flow translate into improvements in the functional capacity measured by the six minute walk test", says Professor Aldo Maggioni, an ESC spokesperson, from the Centre of the Italian Association of Hospital Cardiologists (Florence, Italy). Furthermore, he adds, even improvements in peripheral blood flow were not equal in the arms and legs.

"The cross over design offers a real strength of the study since it allows patients to act as their own controls, but, the small number of patients involved makes statistical analysis unreliable," says Maggioni.

Any future studies undertaken, says Dickstein, will need to involve larger cohorts of patients. "One big question for me is whether four weeks of treatment is sufficient to produce significant effects. This begs the question of whether higher doses and longer durations of treatment might have produced clearer cut answers," he adds.

Recent registries showing a 5 to 8% annual mortality for chronic heart failure patients underline the urgent need for new heart failure treatments in addition to the standard ACE inhibitors, ARBs, beta blockers, aldosterone blockers and devices (implantable cardioverter defibrillators and cardiac resynchronisation therapy). "Since UDCA doesn't involve any of the known mechanisms adding this approach to the standard treatments might result in incremental gains," says Maggioni.

What's undisputed is that UDCA seems to have the ability to fire the imagination. "Part of the appeal of the concept is that it's so intuitively attractive. It provides a biologically plausible hypothesis that's really easy for everyone to understand," says Dickstein.

Reference
1. S. von Haehling, J. C. Schefold, E.A. Jankowska, et al. Ursodeoxycholic Acid in Patients With Chronic Heart Failure: A double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol February 7 2012;59:585.

2. J.M. McCabe, J.R. Teerlink, et al. Bile Salts for the Treatment of Heart Failure: Out on a limb for a gut feeling? Ibid, pp593-4.

The European Society of Cardiology (ESC) represents more than 71,200 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

ESC Press Office:
Tel: 33-4-92-94-86-27
Fax: 33-4-92-94-86-69
Email: press@escardio.org

ESC Press Office | EurekAlert!
Further information:
http://www.escardio.org

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>